Nancy Albert, PhD, Director of Nursing Research and Innovation in the Nursing Institute and Clinical Nurse Specialist in the Kaufman Center for Heart Failure at the Cleveland Clinic Dr Albert is also Adjunct Associate Professor at Case Western Reserve University, Bolton School of Nursing in Cleveland Ohio. Nancy is Immediate Past President of the American Association of Heart Failure Nurses, she is on the Leadership Team for the Council of Cardiovascular Nurses of the American Heart Association and she is actively involved in many nursing and medical association and corporate steering committees including ‘Get with The Guidelines' for the American Heart Association, OPTIMIZE-HF for GlaxoSmithKline and IMPROVE-HF for Medtronic, Inc. Dr Albert conducts nursing research, mentors others in initiating nursing research and is an administrator, clinician, educator and consultant in heart failure and nursing research. She has published many articles and book chapters and has presented both nationally and internationally on a variety of cardiac topics, most notably in heart failure. In October 2006 she received the "Partners in Research" award from the Center for Hospice, Palliative Care & End of Life Studies from the University of South Florida and in March 2007, she received the "CNS Researcher of the Year" award from the National Association of Clinical Nurse Specialists.
Dr. Daly received his medical degree from Washington University in St Louis, and residency training in Clinical Pathology at Barnes-Jewish Hospital. After completing his training, Dr. Daly served as Section Head of Clinical Chemistry at the University of Alabama-Birmingham. Most recently, he worked at Eli Lilly and Company, helping to develop biomarkers to support compounds in the oncology portfolio. Currently, his research interests are focused on the development and validation of novel biomarkers for clinical application.
Paul E. DiCorleto, PhD, is the Chair of the Cleveland Clinic Lerner Research Institute and Professor and Chair, Department of Molecular Medicine, Case Western Reserve University School of Medicine. The Lerner Research Institute (LRI) is home to over 160 principal investigators and 1500 employees performing biomedical research that ranges from cellular and molecular biology to biomedical engineering. The LRI is also home to the Center for Clinical Research, which provides infrastructure support and oversight for all human subjects research at Cleveland Clinic. Research funding from external sources to the LRI exceeded $165 million in 2010 with over $100 million coming from the National Institutes of Health (NIH) and other Federal agencies.
Dr. DiCorleto received his undergraduate training in chemistry at Rensselaer Polytechnic Institute and his doctorate in biochemistry from Cornell University. Dr. DiCorleto's research focuses on the molecular and cellular basis of atherosclerosis. He has been with the Cleveland Clinic since 1982, having served previously as Chairman of the Department of Cell Biology and as an Associate Chief of Staff. He is currently a member of the Clinic's Board of Governors and Board of Trustees.
On a national level, Dr. DiCorleto has chaired multiple NIH and American Heart Association review panels, as well as several national conferences on research into heart and vascular disease. He has published over 100 articles in his field and serves on the editorial board of multiple scientific journals. Dr. DiCorleto has served as President of the North American Vascular Biology Organization, and is currently a member of the Scientific Advisory Board. He also serves as a member of the Association of American Medical Colleges’ Advisory Panel on Research. He was elected a Fellow of the American Association for the Advancement of Science (AAAS) in 2007. Dr.DiCorleto is a Community Board member of the Cleveland State University Board of Trustees. He has served a a consultant and Board member of multiple companies and is currently a director of Cleveland BioLabs, Inc., a publicly traded company.
Dr. Foss came to the Cleveland Clinic in 2005. He is currently active in developing the research program in the Department of General Anesthesiology and is a vice-chair for the Cleveland Clinic Institutional Review Board. As the Director of Clinical Research for the Department he works closely with junior and senior staff in supporting their research activities. He also coordinates with the Department of Outcomes Research in the Anesthesiology Institute. He is an active clinical anesthesiologist providing care for a broad range of general surgery patients. Prior to moving to Cleveland he was with Adolor Inc., a biotech start-up, as a Medical Director. He was responsible for Phase I-III research programs for alvimopan and novel delta and kappa opioid compounds. He was also part of the development team for the Phase III program and acted as the Alliance Coordinator in the collaboration on alvimopan with GSK. Dr. Foss received his undergraduate degree in Biomedical Science and his Medical Degree from Brown University in Providence, Rhode Island. At the University of Chicago he completed clinical training in Anesthesiology and a fellowship year in Clinical Pharmacology where he subsequently joined the faculty. There he led the early clinical development program for methylnaltrexone as well as conducting clinical trials for other drugs and directing the Integrated Anesthesiology Laboratory. The clinical development project for methylnaltrexone included basic and clinical research, managing the regulatory affairs for the drug, and presenting the proposed clinical development program to potential licensees. This effort led to several peer-reviewed publications on both the action of the drug, as well as new information about the potential separation of central and peripheral opioid effects. The drug was licensed by the University and was approved for clinical use in 2008. As one of the named researchers on several patents Dr. Foss also led the negotiations for the monetization of the royalties on behalf of the inventors group.
Dr Griffin has been a cardiologist at the Cleveland Clinic in Cleveland, Ohio since 1993. Cleveland Clinic has been voted the #1 hospital for cardiovascular care for the last 18 years by US News and World Report. Dr Griffin is Head, Section of Cardiovascular Imaging in the Heart and Vascular Institute, Cleveland Clinic since 2012 and Physician Director of Development, Heart and Vascular Institute, Cleveland Clinic since 2004. Prior to this, he was Director of the Cardiovascular Disease Training Program since 1994. From 2003-6, he was Vice-Chairman, Department of Cardiovascular Medicine, Cleveland Clinic and has held the John and Rosemary Brown Endowed Chair in Cardiovascular Medicine at Cleveland Clinic since 2007.
Dr Griffin graduated in medicine in 1979 from University College Galway, National University of Ireland. After completing medical training in Galway and Dublin, he trained at Guy's Hospital, London and at Cedars-Sinai Medical Center, Los Angeles. He was a clinical fellow in cardiology at Boston University Medical Center from 1987-9 and at the Massachusetts General Hospital, Boston from 1989-91. From 1991-93, he was on faculty at Dartmouth Medical School.
Dr Griffin is the author of more than 130 publications in cardiology and has edited 3 cardiology textbooks. The Manual of Cardiovascular Medicine that he edits is in its 4th edition and has been translated into Chinese, Spanish, Greek and Portuguese. He is the US Associate Editor for Heart, the journal of the British Cardiac Society. He received the Stoke's Medal of the Irish Cardiac Society in 2002 and was the recipient of the Medtronic Award for Medicine, Nursing and Health Sciences from the National University of Ireland Galway in 2011.
He is also Professor of Ophthalmology at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University and is a member of the Graduate School Faculty, Kent State University, Kent, Ohio. He was Professor of Cell Biology, Neurobiology and Anatomy at Ohio State University from 1996-2003. He received his PhD degree from the University of Texas at Austin and was a postdoctoral fellow at the Hubrecht Laboratory in Utrecht, The Netherlands. Dr. Hollyfield has previously held faculty positions at Columbia University College of Physicians and Surgeons in New York City and at Baylor College of Medicine in Houston, TX. He was Director of the Foundation Fighting Blindness Research Center in The Cullen Eye Institute at Baylor College of Medicine from 1978 until his move to The Cleveland Clinic Foundation in 1995. Dr. Hollyfield has published over 175 papers in the area of cell and developmental biology. He is currently Editor-in-Chief of the journal, Experimental Eye Research published by Elsevier Science. He has edited nine books. Dr. Hollyfield has received the Marjorie W. Margolin Prize, the Sam and Bertha Brochstein Award, the Award of Merit in Retina Research, the Olga Keith Wiess Distinguished Scholars' Award, two Senior Scientific Investigator Awards, an award for Outstanding Contributions to Vision Research from the Alcon Research Institute, the Distinguished Alumnus Award from Hendrix College, Conway, Arkansas and the Endre A. Balazs Prize from the International Society for Eye Research. Dr. Hollyfield has been active in the Association for Research in Vision and Ophthalmology, as a Trustee and as President. He is also a past President and former Secretary of the International Society of Eye Research. He currently serves on the Scientific Advisory Boards of The Foundation Fighting Blindness, Research to Prevent Blindness, The Helen Keller Eye Research Foundation, The South Africa Retinitis Pigmentosa Foundation, Knights Templar Eye Foundation, and is Co-Chairman of the Medical and Scientific Advisory Board of Retina International.
Director of the Sones Cardiac Catheterization Laboratories in the Robert and Suzanne Tomsich Department of Cardiovascular Medicine. He is board-certified in internal medicine, cardiology and interventional cardiology. As an interventional cardiologist, Dr. Kapadia has a special interest in complex coronary, structural heart disease-related cardiac interventions as well as carotid and peripheral interventions. A native of India, Dr. Kapadia received his medical degree with honors from Smt. N.H.L.M. Medical College in Gujarat, India, and scoring sixth highest out of 30,000 pre-med students on the state boards. He completed his internship and residency in internal medicine at Baylor College of Medicine in Houston, where he was named Outstanding Resident. He came to Cleveland Clinic for a fellowship in cardiology and stayed on for a fellowship in interventional cardiology, and during this time he became Chief Interventional Fellow. Dr. Kapadia was appointed to Cleveland Clinic in 2003 as a staff interventional cardiologist. He is currently also the Director of the Interventional Cardiology Fellowship Program. Prior to his appointment to Cleveland Clinic, Dr. Kapadia had an academic appointment to the Department of Medicine at the University of Washington, and he served as an interventional cardiologist at the Puget Sound Health Care System of the Veterans Administration Hospital in Seattle. Dr. Kapadia has been involved as principal investigator or co-investigator in numerous clinical trials related to percutaneous replacement of aortic valve, percutaneous mitral valve repair, carotid stenting, PFO closure, to name a few. He has been invited to present results of his research at national and international symposia and conferences. He is author or co-author of more than 30 book chapters in medical textbooks on his specialty interests, and he has authored numerous articles and abstracts in medical journals on his clinical experience. Dr. Kapadia is an editorial reviewer for the peer-reviewed medical journals Circulation, Journal of the American College of Cardiology, Cytokine and the Journal of the American Medical Association. He grades abstracts for the American College of Cardiology. Dr. Kapadia is Fellow of the American College of Cardiology and a Member of the American Heart Association. Since 2004, Cleveland Magazine named Dr. Kapadia to its list of "Top Doctors."
Dr. Kattan is the Chairman of the Department of Quantitative Health Sciences at The Cleveland Clinic and Professor of Medicine, Epidemiology and Biostatistics, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. He has a PhD in management information systems with a minor in statistics. He also holds an MBA with concentration in quantitative sciences. Following his studies, he completed a postdoctoral program in medical informatics before joining the faculty at Baylor College of Medicine in Houston, Texas. He has over 300 peer-reviewed publications and is best known for his prediction models, called nomograms, in various cancers. He has received 2 patents for this work and serves on the editorial boards for Cancer Investigation and Nature Clinical Practice Urology. Dr. Kattan is interested in the development, validation, and use of prediction models. He has developed several such models in cancer and released them as freely available software, from http://www.nomograms.org. Dr. Kattan is also interested in quality of life assessment to support medical decision making, such as utility assessment. Other interests include decision analysis and cost-effectiveness analysis.
Dr. Labhasetwar received his undergraduate and PhD degrees in Pharmaceutical Sciences from Nagpur University in India. He was a staff scientist at the National Institute of Immunology in New Delhi (1988-90) before coming to the United States as a postdoctoral fellow in the School of Medicine and College of Pharmacy, University of Michigan, Ann Arbor. After completing his training in 1993, Dr. Labhasetwar continued at the University of Michigan as a faculty member until 1997. He then joined the University of Nebraska Medical Center as Associate Professor of Pharmaceutical Sciences and Biochemistry and Molecular Biology. In February 2007, Dr. Labhasetwar became a Staff member of the Cleveland Clinic's Department of Biomedical Engineering, where he leads the Cancer NanoMedicine program, a collaborative effort jointly sponsored by Biomedical Engineering and the Clinic's Taussig Cancer Center. His research interests are in translational nanomedicine. Dr. Labhasetwar's laboratory investigates nanosystems for drug/gene delivery in cancer therapy, stroke, cardiovascular conditions, and other age-related disorders. He has developed multifunctional magnetic nanoparticles which he is investigating for imaging and targeted delivery of therapeutics in cancer treatment. He also studies nanoparticle-cell interactions to understand the molecular mechanism of intracellular trafficking of nanoparticles. His research has been funded primarily by the National Institutes of Health, the Department of Defense, and the American Heart Association. He has published over 100 peer-reviewed articles and book-chapters, and holds several U.S. and international patents. He has recently co-edited the book, Biomedical Applications of Nanotechnology, which will be published by John Wiley & Sons, Inc., in July 2007. He is the editor-in-chief of Journal of Biomedical Nanotechnology.
Dr. Machado is the Director of the Center for Neurological Restoration in the Neurological Institute. Dr. Machado performs deep brain stimulation (DBS) surgery for patients with Parkinson's disease, tremor, dystonia and psychiatric disorders as well as surgical procedures for patients with intractable pain syndromes and spasticity. Dr. Andre Machado received his medical degree from the University os Sao Paulo in 1997. He completed his residency in the same institution in 2003 and obtained his PhD in 2004. He came to the Cleveland Clinic in 2004, completed his fellowship in Stereotactic and Functional Neurosurgery in 2006 and has been on the staff of the Cleveland Clinic since then. Dr. Machado is an Assistant Professor of surgery at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University and Associate Staff in the Department of Neurosurgery with Joint Appointments in the Departmetn of Neuroscience and in the Department of Biomedical Engineering at the Cleveland Clinic Lerner Research Institute. Dr. Machado is the program director for education in Sterotactic and Functional Neurosurgery and won the "Teacher of the year award" from the Department of Neurosurgery in 2009. Dr. Machado leads deep brain stimulation and neuromodulation clinical trials as well as laboratory research. His research in deep brain stimulation for thalamic pain syndrome was awarded the National Institutes of Health Director's New Innovator's Award. In addition, he conducts deep brain stimulation research for treatment refractory depression as well as obsessive compulsive disorder. His laboratory in the Lerner Research Institute is focused in developing new strategies for utilizing neuroprostetic devices such as DBS to improve post-stroke rehabilitation. His current NIH funded research is aimed at evaluating the effects of deep cerebellar stimulation on post-stroke perilesional plasticity and recovery of function. Dr. Machado is the author of several peer reviewed publications and chapters in stereotactic and functional neurosurgery.
Dr. Macklis received his medical degree from Harvard Medical School, Boston, MA. He did his internship at Brigham & Women's Hospital in Boston, MA and completed his residency at the Joint Center for Radiation Therapy at Harvard Medical School. His specialty interests include the use of therapeutic radiation for the management of lymphoma, breast cancer, pediatric solid tumors, research investigations in automation and robotics in oncology, automated quality assurance procedures, and new types of biologically targeted radiotherapy such as radioimmunotherapy. Dr. Macklis is available to see patients at the main campus location in Cleveland.
Dr. Papay, an accomplished surgeon, has been recognized as one of the nation's Best Doctor specializing in plastic surgery by Castle Connolly. He is the current chairman of the Cleveland Clinic's Dermatology and Plastic Surgery Institute and associate professor of surgery, Lerner School of Medicine of Case Western Reserve University. He is head of the section of craniofacial surgery and leads the multidisciplinary craniofacial cleft palate surgical center of the Cleveland Clinic. His clinical research interests include utilization of bone substitutes in craniofacial reconstruction, nasal valve function in rhinoplasty, facial aesthetic plastic surgery, pediatric craniofacial anomalies, surgical techniques in face allograft transplants and neural modulation of skull base ganglia. Dr. Papay has served as President of the Ohio Valley Society of Plastic Surgeons, elected Chair of the American Society of Plastic Surgery's Ethics Committee, President of the Plastic Surgery Section of the American Academy of Pediatrics and of the Academy of Medicine of Cleveland and Northern Ohio. He has published over 100 scientific papers, abstracts and book chapters and is the primary inventor of eight medical device patents and craniofacial surgical procedures. He has served as an invited Board Examiner for the American Board of Plastic Surgery, Finalist Judge for the collegiate inventors' competition from the National Inventors Hall of Fame and invited section reviewer and/or editorial board of several plastics surgery scientific journals. He has also served on several overseas volunteer surgical missions for craniofacial and cleft palate reconstructions. Dr. Papay is currently completing his Executive Doctor of Management degree at the Weatherhead School of Management, Case Western Reserve University, with his thesis interest in decision-making analysis of risk by financiers of new biotech innovations and technology transfer.
Dr. Phillips, a member of the Department of Diagnostic Radiology, Section of Neuroradiology, since 2002, has lectured nationally and internationally on radiology-related topics. As a member of the Imaging Institute, he serves as the Head of the Section of Imaging Sciences. His clinical efforts in neuroradiology have focused on functional neuroimaging and he developed the functional MRI and DTI protocols that are used clinically for pre-surgical planning for both tumor and epilepsy surgery. Dr. Phillips earned his medical degree from Columbia University College of Physicians and Surgeons. He also trained in Diagnostic Radiology at Johns Hopkins Hospital and, subsequently, completed a fellowship in Neuroradiology at the University of Pennsylvania Medical Center.
John P. Pigott, MD, FACS, medical director, ProMedica Innovations, is a recognized leader in medical innovations and vascular surgery. He is founder and president of VentureMed Group, a medical device company involved in the treatment of peripheral artery disease and a founding member of Vascular Innovations, a company devoted to novel technologies for aortic aneurysms. A member of Cleveland Clinic Innovations Commercialization Advisory Board, Dr. Pigott holds his own patents for devices involving aortic aneurysm and peripheral artery technologies. He serves as a consultant to numerous multinational medical device companies and conducts national and regional new device training programs.
Dr. Pigott was an early proponent of minimally invasive endovascular treatment for abdominal aortic aneurysms, carotid artery and peripheral artery disease and was a principal investigator for national clinical trials studying these techniques. He has authored multiple articles in peer-reviewed medical journals and presents at regional and national vascular meetings.
As a board-certified vascular surgeon at Jobst Vascular Institute (JVI) and ProMedica Toledo Hospital, Dr. Pigott serves as a faculty member of the ACGME-accredited Jobst Vascular Fellowship Program. Dr. Pigott received his medical degree from the Medical College of Ohio, completed his residency at Akron City Hospital, and is fellowship-trained by Mayo Clinic.
Richard is Director of the Neuroinflammation Research Center in the Dept. of Neurosciences of the Lerner Research Institute, Professor of Molecular Medicine at the Cleveland Clinic Lerner College of Medicine, and Staff Neurologist in the Mellen Center for MS Treatment and Research, both at the Cleveland Clinic Foundation (CCF), Cleveland, OH. Dr. Ransohoff graduated with honors from Bard College, Annandale, NY with a B.A. in Literature, and received the M.D. degree with honors from Case School of Medicine, Cleveland, OH. He completed residencies in Internal Medicine (Mt. Sinai Medical Center, Cleveland, OH; Board Certified 1981) and Neurology (CCF; Board Certified 1985). From 1984 until 1989, Dr. Ransohoff was a post-doctoral fellow in the laboratory of Dr. Timothy Nilsen, Dept. of Molecular Biology and Microbiology, Case School of Medicine. Dr. Ransohoff served as regular member on study sections of the NIH and NMSS (as Chair). He has served on the Editorial Boards of The Journal of Immunology, (2002-2005 as Section Editor) Trends in Immunology, the Journal of Neuroimmunology; Nature Reviews Immunology, and Neurology (Associate Editor). He is a member of the Steering Committee for the NIH Therapeutic Development Program in Spinal Muscular Atrophy; the International Advisory Boards for the 7th (2004) and 8th (2006) Congresses on Neuroimmunology; and the Scientific Advisory Board for Chemocentryx, Mountain View, CA. He serves on External Advisory Boards for CHARTER (CNS HIV Anti-Retroviral Therapy Effects Research; MH22005); a Program Project on Alexander's Disease (NS 42803); the MS Lesion Project (NMSS RG 3185); the University of Nebraska's Center for Neurovirology & Neurodegenerative Disorders (NS43985) and was the External Advisor for the European Union's Project on 'Mechanisms of Brain Inflammation" (QLG3-00612). He is a member of the National MS Society's Medical Advisory Board. He is the Co-director of the Marine Biological Laboratory's special topics course on "Pathogenesis of neuroimmunological disease" held biennially at Wood's Hole, MA. He is a member of the External Advisory Board for Meharry Medical College's Special Neuroscience Research Program (SNRP). For the past decade, Dr. Ransohoff's research has focused on the functions of chemokines and chemokine receptors in development and pathology of the nervous system. He also has a longstanding and continuing interest in the mechanisms of action of interferon-beta. Dr. Ransohoff has received research support from the NIH and the NMSS. He has published more than 150 scientific reports, more than 50 reviews and book chapters, and three edited books. Dr. Ransohoff is a member of the American Academy of Neurology, the American Neurological Association, the American Association for the Advancement of Science and the American Association of Immunologists.
Dr. Rome currently serves as Associate Chief of Staff and as Head of the Section of Adolescent Medicine. She is a board certified pediatrician who was also among the first in the United States to be board certified in Adolescent Medicine. Dr. Rome received her undergraduate degree in psychology, magna cum laude, from Yale University in 1984. She received her medical degree and was initiated into Alpha Omega Alpha in 1988 from Case Western Reserve University's School of Medicine, then completed an internship and residency in pediatrics at Johns Hopkins Hospital. She next completed a three year fellowship in adolescent medicine at Children's Hospital, Boston, during which time she also obtained a masters degree in Public Health at the Harvard University School of Public Health. Dr. Rome currently serves as an Associate Professor of Pediatrics at the Cleveland Clinic Lerner College of Medicine at Case. She helped start the first Adolescent Health track at the new school of public health at Case Western Reserve, and coordinates the Adolescent Medicine rotation at the Cleveland Clinic for residents and medical students. She serves as Media Chair and on the Public Affairs Committee for the Academy for Eating Disorders, is on the board of the North American Society for Pediatric and Adolescent Gynecology, and is an examiner for IFEPAG, or the international pediatric and adolescent gynecology society. Dr. Rome's research interests include eating disorders and obesity, preventive medicine, and reproductive health. She has been an invited speaker locally, nationally, and internationally on various topics in adolescent medicine, while maintaining a commitment to ongoing teaching of house staff and students in the local and surrounding areas. She has written and published on various adolescent medicine topics, including eating disorders and obesity, the female athlete triad, nutrition for the teen athlete, and adolescent sexuality.
Graduate of Medical School in Rosario, Argentina. Trained as a general surgeon at the Provincial Hospital in Rosario Argentina between 1981 and 1983.Emigrated to Germany to repeat medical degree and general surgical residency training between 1983 and 1990. Revalidated the MD degree and obtained title of general surgeon from the German Society of Surgeons. Worked as attending surgeon at the University Hospital, Krankenhaus Nordwest , Frankfurt, Germany during the period of 1990-1993. In 1993 emigrated to the US to work as a research fellow in MIS at UCLA/Cedars Sinai Medical Center until 1996. Revalidated MD degree( ECFMG) and repeated surgical residency training at The Mount Sinai Medical Center in New York between 1996-1999. Since 1999 Chairman of the Department of Minimally Invasive and Bariatric Surgery at Cleveland Clinic Florida. Professor of Surgery Florida International University and Associate professor of surgery at the University of South Florida. Director of the Minimally Invasive and Bariatric Fellowship Program. Cleveland Clinic, Weston Florida. Fellow of the American College of Surgeons, Fellow of the German Society of Surgery and Corresponding Fellow of the Argentinian Society of Surgery. He is a Fellow of the American Society of Metabolic and Bariatric Surgeons and Honorary Fellow of the German Society of Visceral Surgery. Active Member of the Board of Governors of SAGES. Chair of the International Centers of Excellence Program in Bariatric Surgery of the SRC. Co-Chair of the Go Global Initiative, SAGES. Chair of the International Committee of the ASMBS and active member of the Executive Board of the Fellowship Council. Active Member of the Training Committee, Institutional Relations, Clinical Outcomes and Emerging Technology Committees of The American Society of Metabolic and Bariatric Surgeons. Secretary and Board Member of the SAGES education and research Foundation. Dr. Rosenthal is the editor of Bariatric Times Magazine, is member of the editorial board of Obesity Surgery and Journal of Surgical Oncology. Dr. Rosenthal has published over 150 papers in peer reviewed journals, is conducting multiple FDA and clinical research trials. In addition, he is the editor of 3 textbooks in general and endoscopic surgery and author of over 50 chapters in general surgery books.
Yogen is an Associate Staff in the Department of Hematologic Oncology and Blood Disorders with a secondary appointment in the Department of Translational Hematology and Oncology Research at the Taussig Cancer Institute of the Cleveland Clinic, and an Associate Professor and the Cleveland Clinic Lerner College of Medicine at CWRU. Dr. Saunthararajah received undergraduate and medical degrees from the University of Wales College of Medicine, and completed medical and surgical internships at University Hospitals of Wales, United Kingdom. Dr. Saunthararajah served as a Captain (Military Medicine) in the Singapore Armed Forces, Singapore. A major objective of his laboratory's work is to develop therapy that selectively destroys malignant cells while sparing normal stem cells. To this end, the work covers a number of aspects: one aspect focuses on understanding the mechanisms by which malignant stem cells self-renew, and finding differences between malignant self-renewal and normal stem cell self-renewal. Another aspect focuses on identifying and developing drug-able compounds that target identified differences between normal and malignant self-renewal. A final aspect studies the pharmacologic properties and considerations of proposed agents to enable the clinical trials for selective malignant stem cell destruction. The other major objective of his efforts is to develop more effective methods for pharmacologic reactivation of fetal hemoglobin expression as a treatment for sickle cell disease and beta-thalassemia.
Dr. Schaffer is Technology and Systems Chief in the Adult Reconstruction Section and leads the Advanced Operative Technology Group in the Orthopaedic Clinical Research Center and the Department of Orthopaedic Surgery at Cleveland Clinic. His clinical interests include the treatment of arthritic knees and the application of new technologies in surgical care. Dr. Schaffer is an active member of many professional societies including the American College of Physician Executives, the American Orthopaedic Association, the American Society for Quality and the American Medical Informatics Association. He is an elected fellow of the Healthcare Information and Management Systems Society and the American Academy of Orthopaedic Surgeons and was named to the Alpha Omega Alpha Honor Medical Society. He is also active with public safety forces including his services to his community as an on-call firefighter and police department surgeon. A frequent lecturer at regional, national and international information technology and medical meetings, Schaffer has authored more than 125 articles, book chapters and textbooks. In addition, he has developed a number of multimedia programs and computer software applications on patient outcomes, process engineering and patient education. He and his teams have received several awards for medical Web site development. Dr. Schaffer is a graduate of Case Western Reserve University School of Medicine in Cleveland. He completed his internship and residency in orthopaedic surgery at the University of Pennsylvania Affiliated Hospitals in Philadelphia. He completed a fellowship in adult reconstruction at the Brigham and Women's Hospital and Harvard Medical School in Boston and a research fellowship at Children's Hospital of Boston and Harvard Medical School. Dr. Schaffer also holds a Master's in Business Administration from the Kellogg Graduate School of Management at Northwestern University in Evanston, Ill. Prior to his appointment at The Cleveland Clinic, he was Assistant Professor of Orthopaedic Surgery at Harvard Medical School and Brigham and Women's Hospital in Boston. At Harvard, Dr. Schaffer was also Associate Director of the Decision Systems Group, a medical informatics laboratory and Chief Executive Officer of Harmonie Group, Inc., a software company spun off from the laboratory with external funding.
Dr. Soltesz is part of a multidisciplinary team of health care providers who specialize in thoracic and cardiovascular surgery and transplant medicine. Dr. Soltesz's health care team guides the treatment and coordination of patient care. Dr. Soltesz completed an additional fellowship in complex aortic and endovascular surgery at Cleveland Clinic and was appointed to the Department of Thoracic and Cardiovascular Surgery in 2008. Dr. Soltesz is the author of numerous articles in the areas of minimally invasive surgery, optical imaging in cardiac surgery, near-infrared fluorescence imaging, and complex valve surgery.
Kevin J Tracey, MD is president and CEO of the Feinstein Institute for medical research. An inventor and neurosurgeon, Tracey is a leader in the field of inflammation research. His highly cited papers have formed the basis for several new technologies and start-up companies.
Geoffrey Vince, PhD, holds The Virginia Lois Kennedy Chair in Biomedical Engineering and Applied Therapeutics in the Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.
Educated in his native England, Dr. Vince obtained his PhD in biomedical engineering from the University of Liverpool in 1989. He came to Cleveland Clinic's Department of Biomedical Engineering (BME) as a Postdoctoral Research Fellow in 1992, rising to Associate Staff by 2003. While in BME, Dr. Vince and colleagues invented a new methodology for imaging the interior of coronary arteries using intravascular ultrasound. This methodology, "Virtual Histology™," was patented and later licensed to Volcano Therapeutics (now Volcano Corp.). To further develop his technology through to a product, Dr. Vince left Cleveland Clinic to join Volcano's Cleveland office in 2005 as Director of Research. In 2006, he became Vice-President of Clinical and Advanced R&D, moving to Volcano's headquarters in San Diego, California; much of his experience there involved international travel and a grasp of issues of technology transfer and intellectual property as viewed in several countries; his own invention has now become a product of some 5000 units worldwide.
In 2011, Dr. Vince was recruited back to Cleveland Clinic, this time as Chair of his former department. The reason? "Biomedical engineering is a perfect mixture of basic science, translational research, and clinical research."
Throughout his career, Dr. Vince's research has been awarded funding from the National Institutes of Health, the American Heart Association, and many corporate sources. He is an inventor on more than 60 patents or patent applications in the U.S. and worldwide. He has served as an expert reviewer on NIH study sections and for several scientific publications. He has reported his own group's findings in dozens of highly rated scientific, clinical, and engineering oriented journals. Most recently, in March 2012, the American College of Cardiology issued a Supplement in its journal JACC-Cardiovascular Imaging consisting of articles based on the use of his Virtual Histology technique. Earlier while in Cleveland, he was a mentor to numerous students and postdoctoral fellows.
Neil J. Weissman, MD, FACC, is president for MedStar Health Research Institute, professor of medicine at Georgetown University School of Medicine and director of the ultrasound core laboratories at the Cardiovascular Research Institute at Washington Hospital Center in Washington, D.C.
Weissman's research interests include valvular heart disease, left ventricular remodeling and intravascular imaging. His ultrasound core laboratory has served as a site for over 100 multi-center trials, including multiple studies on pharmacologic effects of valvular and ventricular function, prosthetic valve assessments, and intracoronary therapies. Additionally, Weissman has served as principal investigator for numerous national and international multi-center trials, and is currently the national principal investigator on a cardiac safety study with over 3,500 participants. Prior to moving to the Washington Hospital Center, he was the director of the clinical echo lab at Georgetown University.
Weissman received his medical degree from Cornell University Medical College in New York. He then completed his internship, residency, and chief residency in internal medicine at New York Hospital in New York. He followed his residency training with a clinical and research fellowship in cardiology and a fellowship in cardiac ultrasound at Massachusetts General Hospital in Boston, Massachusetts.
Internationally recognized as an expert in cardiac ultrasound, Weissman has served on several national organizations, and is on several editorial boards for various internationally recognized journals. He has published hundreds of abstracts and original reports, as well as written several review articles and book chapters. Most recently, he wrote a textbook on cardiac imaging.
Karl West is Cleveland Clinic’s Director of Medical Device Solutions. He has been in this position since April of 2010. Karl has worked at the Clinic for more than nine years in the Department of Biomedical Engineering developing medical devices. He is an expert in device design with a concentration in aortic replacement devices such as multi-branched endovascular prosthesis. Before starting his career at Cleveland Clinic, Karl was employed by Philips Medical System acting as the lead engineer on computed tomography R&D projects.
Innovations has facilitated several Cleveland Clinic Spin-Offs over the last decade. Click here to see our current portfolio.Read More
The Alliance network strives to realize new opportunities for innovation by gaining a 360-degree perspective on healthcare and its future.Read More